Showing papers by "Julie M. Vose published in 2005"
TL;DR: No case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy and with a median follow-up approaching 5 years, consistent with that expected on the basis of patients' prior chemotherapy for NHL.
157 citations
TL;DR: There were no significant added toxicities apparent with the addition of iodine-131 tositumomab up to a dose of 0.75 Gy TBD to high-dose BEAM chemotherapy followed by ASCT, and the EFS and OS were encouraging in this group of chemotherapy-resistant or refractory B-cell NHL patients.
Abstract: Purpose To determine the maximum outpatient dose of iodine-131 tositumomab (up to 0.75 Gy) combined with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous stem-cell transplantation (ASCT) for the treatment of chemotherapy-resistant relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Patients and Methods Twenty-three patients with chemotherapy-refractory or multiply-relapsed B-cell NHL were treated in a phase I trial combining iodine-131 tositumomab (ranging from 0.30 to 0.75 Gy total-body dose [TBD]) with high-dose BEAM followed by ASCT. Results The complete response rate after transplantation was 57%, and the overall response rate was 65%. Short-term and long-term toxicities were similar to historical control patients treated with BEAM alone. With a median follow-up of 38 months (range, 27 to 60 months), the overall survival (OS) rate was 55%, and the event-free survival (EFS) rate was 39%. Conclusion There were no significant added toxicities apparent with ...
156 citations
TL;DR: Cyclin D2 and PKC-β expression will be useful in designing a ‘biological prognostic index’ for patients with DLBCL.
120 citations
TL;DR: Treatment of MCL with HyperCVAD +/- rituximab followed by HSCT seems promising, and patients treated with allogeneic HSCT had a lower relapse rate, but similar EFS and OS to autologous HSCT.
76 citations
TL;DR: The data suggest that HGS-ETR1 has activity in heavily pretreated lymphoma patients and further studies in combination with agents active in lymphoma are justified, and can be safely administered to heavily treated NHL patients.
75 citations
TL;DR: A multivariate analysis of the two most common types, PTCL-unspecified and angioimmunoblastic, demonstrated the following factors to predict poor OS: poor performance status, age > 60 years, platelets < 150K, and factors associated with worse FFS.
65 citations
TL;DR: There are some cGVHD prognostic factors that may be unique to recipients of alloPBSCT that suggest more studies are needed to determine whether cGV HD prognostic systems should be used interchangeably in patient populations receiving different stem‐cell products.
Abstract: Allogeneic hematopoietic stem cells in peripheral blood transplantation (alloPBSCT) or bone marrow transplantation (alloBMT) have different biological characteristics which may affect differently prognostic factors for incidence and severity of chronic graft-versus-host disease (cGVHD). To determine the prognostic factors of cGVHD in patients receiving alloPBSCT, data on 87 patients who survived at least 100 days after matched related donor myeloablative transplantation were analyzed. Factors significantly associated with higher incidence of cGVHD after alloPBSCT included CMV-positive donor, acute skin GVHD, and diagnoses other than lymphoma. Factors predictive for poor survival following cGVHD diagnosis included platelet count < 100,000/mm3 and history of acute liver GVHD. Acute liver GVHD and etoposide in the preparative regimen significantly increased risk of death due to cGVHD after alloPBSCT. All alloPBSCT multivariate models were fit to an independent cohort of comparable matched related donor alloBMT patients (n=75). After alloBMT, only acute skin GVHD and diagnoses other than lymphoma retained prognostic significance for predicting cGVHD. Low platelet count was the only variable predictive for poor survival in cGVHD patients after alloBMT. Acute liver GVHD was the only factor that retained prognostic significance for risk of death due to cGVHD after alloBMT. These data suggest there are some cGVHD prognostic factors that may be unique to recipients of alloPBSCT. More studies are needed to determine whether cGVHD prognostic systems should be used interchangeably in patient populations receiving different stem-cell products.
62 citations
TL;DR: The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.
Abstract: The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL). Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m(2) per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy. Currently, the patients now have a median follow-up of 63 months (range 34 - 82 months). The overall response (OR) rate was 94% and the complete response (CR) rate was 61% at the end of therapy. Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months. The 5-year survival rate was 88% (95% confidence interval (CI) 72 - 97) and the 5-year progression-free survival was 82% (95% CI 64 - 93). There were no long-term adverse events noted directly related to the rituximab. The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.
46 citations
TL;DR: Bortezomib can be administered with acceptable toxicity in conjunction with CHOP-R chemotherapy in patients with DLBCL and MCL, and preliminary findings with the combination regimen in this adverse prognosis group of patients are encouraging.
40 citations
Journal Article•
TL;DR: The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide, and options include various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation.
Abstract: The most common indolent lymphoma, follicular lymphoma comprises 35% of adult non-Hodgkin's lymphoma (NHL) in the United States and 22% worldwide. Features associated with adverse outcome include age, male gender, disease stage, and performance status, with the International Prognostic Index being the most widely used risk classification system. Long-term disease-free survival is possible in select patient subgroups after treatment, but very late relapses suggest that quiescent lymphoma cells might be harbored for long periods of time. Radiation therapy is the mainstay of treatment for limited-stage follicular lymphoma, but there is some experience with chemotherapy and combined chemoradiation. When to initiate treatment in patients with advanced disease is controversial, but options include various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation. Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, and proteasome inhibitors.
28 citations
TL;DR: Efficacy is summarized by line of therapy, and all differences are highly statistically significant.
Abstract: 6561 Background: Tositumomab and Iodine I 131 Tositumomab (the BEXXAR Therapeutic Regimen) has been studied in clinical trials of pts with previously untreated, relapsed, and refractory NHL. The re...
TL;DR: These results suggest that patients with a poorer prognosis according to their FLIPI score can achieve significant remissions following treatment with MyVax® Personalized Immunotherapy.
Journal Article•
TL;DR: It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma, which has the potential to generate immunologic memory, which could provide prolonged remission.
Abstract: The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome. Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies. This therapeutic modality appears safe, with the most common adverse events being transient, local reactions at the site of injection. Furthermore, personalized immunotherapy has the potential to generate immunologic memory, which could provide prolonged remission. Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma. It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.
TL;DR: In this paper, the authors present an update on lymphoma management 13.158.1] and 13.1.2.0.1..., 13.13.
Abstract: 158. Update on lymphoma management 13
TL;DR: The absence of differences in the outcomes of patients with or without ACP suggests that engagement in ACP is not reflective of HSCT risk, and that a policy of discussing ACP with all HSCT patients will not result in universal acceptance of ACP.
TL;DR: In the absence of a prospective cohort study it appears that elimination of TBI from auto-SCT conditioning regimens at UNMC has decreased the risk of sAML/MDS as shown by fewer occurrences after the mid-1990s and in those who did not receive TBI in comparison toThose who did.
TL;DR: In this paper, the potential for long term disease-free survival for patients with recurrent follicular lymphoma receiving high-dose chemotherapy and an autologous hematopoietic stem cell transpl...
Abstract: 6567 Background: The potential for long term disease-free survival for patients with recurrent follicular lymphoma receiving high-dose chemotherapy and an autologous hematopoietic stem cell transpl...
TL;DR: Patients with older age, elevated serum creatinine level, history of previous arrhythmia, or history ofPrevious mediastinal irradiation are more likely to develop AF following an auto-HSCT.